Skip to content

Study · Systematic review · 2026

14 results

Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials.

Khan BW, Agha SA, Qamar I, Khattak MH, Rehman A, Qazi TI, Siddiqui SA, Zeeshan N, Khan UZ, Bibi H, Khan MF, Khan HW, Mian AM, Rafay MA

Naunyn-Schmiedeberg's archives of pharmacology17 Aug 2026

PMID42608559 (opens in a new tab)DOI10.1007/s00210-026-05809-5 (opens in a new tab)PepBankPUB-42608559
Publisher pagePubMedAsk about this study
Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In people with overweight or obesity, CagriSema produced greater weight loss than semaglutide alone, which isolates the effect of adding cagrilintide.

    In plain wordsIn people with overweight or obesity, adding cagrilintide to semaglutide (CagriSema) gave more weight loss than semaglutide alone.

    Peptide
    Cagrilintide
    Outcome
    DecreaseWeight loss, CagriSema vs semaglutide
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference in weight
    −7.58 kg
    CagriSema vs semaglutide

    Source sentences

    Summary
    CagriSema produced significantly greater weight loss than semaglutide (MD = -7.58 kg; 95% CI = -10.30 to -4.86; p < 0.00001
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of CagriSema, a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, compared with placebo, cagrilintide, or semaglutide monotherapy in overweight or obese individuals.
    Summary · context
    Seven randomized controlled trials (RCTs) (n = 8,069) were included.
  2. 02HumanSystematic reviewEfficacy outcome

    In people with overweight or obesity, CagriSema produced greater weight loss than cagrilintide alone, which isolates the effect of adding semaglutide.

    In plain wordsIn people with overweight or obesity, adding semaglutide to cagrilintide (CagriSema) gave more weight loss than cagrilintide alone.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss, CagriSema vs cagrilintide
    Study

    n: not reported in source

    Comparator
    Cagrilintide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference in weight
    −9.24 kg
    CagriSema vs cagrilintide

    Source sentences

    Summary
    cagrilintide (MD -9.24 kg; 95% CI -10.46 to -8.02, p < 0.00001
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of CagriSema, a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, compared with placebo, cagrilintide, or semaglutide monotherapy in overweight or obese individuals.
    Summary · context
    Seven randomized controlled trials (RCTs) (n = 8,069) were included.

Studies that did not test the peptide alone12

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 03HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In people with overweight or obesity, CagriSema produced greater weight loss than semaglutide alone; the contrast does not remove semaglutide.

    In plain wordsIn people with overweight or obesity, the combination CagriSema gave more weight loss than semaglutide alone.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss, CagriSema vs semaglutide
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Mean difference in weight
    −7.58 kg
    CagriSema vs semaglutide

    Source sentences

    Summary
    CagriSema produced significantly greater weight loss than semaglutide (MD = -7.58 kg; 95% CI = -10.30 to -4.86; p < 0.00001
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of CagriSema, a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, compared with placebo, cagrilintide, or semaglutide monotherapy in overweight or obese individuals.
    Summary · context
    Seven randomized controlled trials (RCTs) (n = 8,069) were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 04HumanNot a test of Cagrilintide aloneSystematic reviewEfficacy outcome

    In people with overweight or obesity, CagriSema produced greater weight loss than cagrilintide alone; the contrast does not remove cagrilintide.

    In plain wordsIn people with overweight or obesity, the combination CagriSema gave more weight loss than cagrilintide alone.

    Peptide
    Cagrilintide
    Outcome
    DecreaseWeight loss, CagriSema vs cagrilintide
    Study

    n: not reported in source

    Comparator
    Cagrilintide
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Mean difference in weight
    −9.24 kg
    CagriSema vs cagrilintide

    Source sentences

    Summary
    cagrilintide (MD -9.24 kg; 95% CI -10.46 to -8.02, p < 0.00001
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of CagriSema, a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, compared with placebo, cagrilintide, or semaglutide monotherapy in overweight or obese individuals.
    Summary · context
    Seven randomized controlled trials (RCTs) (n = 8,069) were included.

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  3. 05HumanNot a test of Cagrilintide aloneSystematic reviewEfficacy outcome

    In people with overweight or obesity, CagriSema produced greater weight loss than placebo.

    In plain wordsIn people with overweight or obesity, the combination CagriSema gave more weight loss than placebo.

    Peptide
    Cagrilintide
    Outcome
    DecreaseWeight loss, CagriSema vs placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Mean difference in weight
    −13.99 kg
    CagriSema vs placebo

    Source sentences

    Summary
    placebo (MD = -13.99 kg; 95% CI = -18.38 to -9.61; p < 0.00001
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of CagriSema, a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, compared with placebo, cagrilintide, or semaglutide monotherapy in overweight or obese individuals.
    Summary · context
    Seven randomized controlled trials (RCTs) (n = 8,069) were included.

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  4. 06HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In people with overweight or obesity, CagriSema produced greater weight loss than placebo.

    In plain wordsIn people with overweight or obesity, the combination CagriSema gave more weight loss than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss, CagriSema vs placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Mean difference in weight
    −13.99 kg
    CagriSema vs placebo

    Source sentences

    Summary
    placebo (MD = -13.99 kg; 95% CI = -18.38 to -9.61; p < 0.00001
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of CagriSema, a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, compared with placebo, cagrilintide, or semaglutide monotherapy in overweight or obese individuals.
    Summary · context
    Seven randomized controlled trials (RCTs) (n = 8,069) were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  5. 07HumanNot a test of Cagrilintide aloneSystematic reviewEfficacy outcome

    In people with overweight or obesity, lipid parameters improved with CagriSema versus placebo.

    In plain wordsIn people with overweight or obesity, blood lipid measures improved with the combination CagriSema compared with placebo.

    Peptide
    Cagrilintide
    Outcome
    Not applicableLipid parameters
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight

    Source sentences

    Summary
    lipid parameters improved versus placebo.
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of CagriSema, a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, compared with placebo, cagrilintide, or semaglutide monotherapy in overweight or obese individuals.
    Summary · context
    Seven randomized controlled trials (RCTs) (n = 8,069) were included.

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  6. 08HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In people with overweight or obesity, lipid parameters improved with CagriSema versus placebo.

    In plain wordsIn people with overweight or obesity, blood lipid measures improved with the combination CagriSema compared with placebo.

    Peptide
    Semaglutide
    Outcome
    Not applicableLipid parameters
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight

    Source sentences

    Summary
    lipid parameters improved versus placebo.
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of CagriSema, a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, compared with placebo, cagrilintide, or semaglutide monotherapy in overweight or obese individuals.
    Summary · context
    Seven randomized controlled trials (RCTs) (n = 8,069) were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  7. 09HumanNot a test of Cagrilintide aloneSystematic reviewEfficacy outcome

    In people with overweight or obesity, glycemic outcomes with CagriSema were heterogeneous across trials.

    In plain wordsIn people with overweight or obesity, blood sugar results with the combination CagriSema varied between trials.

    Peptide
    Cagrilintide
    Outcome
    MixedGlycemic outcomes
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Glycemic outcomes were heterogeneous
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of CagriSema, a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, compared with placebo, cagrilintide, or semaglutide monotherapy in overweight or obese individuals.
    Summary · context
    Seven randomized controlled trials (RCTs) (n = 8,069) were included.

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  8. 10HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In people with overweight or obesity, glycemic outcomes with CagriSema were heterogeneous across trials.

    In plain wordsIn people with overweight or obesity, blood sugar results with the combination CagriSema varied between trials.

    Peptide
    Semaglutide
    Outcome
    MixedGlycemic outcomes
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Glycemic outcomes were heterogeneous
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of CagriSema, a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, compared with placebo, cagrilintide, or semaglutide monotherapy in overweight or obese individuals.
    Summary · context
    Seven randomized controlled trials (RCTs) (n = 8,069) were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  9. 11HumanNot a test of Cagrilintide aloneSystematic reviewSafety outcome

    In people with overweight or obesity, adverse events with CagriSema were primarily gastrointestinal and injection-site reactions.

    In plain wordsIn people with overweight or obesity, side effects of the combination CagriSema were mostly stomach and gut problems and injection-site reactions.

    Peptide
    Cagrilintide
    Outcome
    Not applicableAdverse event types
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Adverse events were primarily gastrointestinal and injection-site reactions
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of CagriSema, a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, compared with placebo, cagrilintide, or semaglutide monotherapy in overweight or obese individuals.
    Summary · context
    Seven randomized controlled trials (RCTs) (n = 8,069) were included.

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  10. 12HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In people with overweight or obesity, adverse events with CagriSema were primarily gastrointestinal and injection-site reactions.

    In plain wordsIn people with overweight or obesity, side effects of the combination CagriSema were mostly stomach and gut problems and injection-site reactions.

    Peptide
    Semaglutide
    Outcome
    Not applicableAdverse event types
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Adverse events were primarily gastrointestinal and injection-site reactions
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of CagriSema, a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, compared with placebo, cagrilintide, or semaglutide monotherapy in overweight or obese individuals.
    Summary · context
    Seven randomized controlled trials (RCTs) (n = 8,069) were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  11. 13HumanNot a test of Cagrilintide aloneSystematic reviewSafety outcome

    In people with overweight or obesity, CagriSema was not linked to an increase in serious adverse events.

    In plain wordsIn people with overweight or obesity, the combination CagriSema was not linked to more serious side effects.

    Peptide
    Cagrilintide
    Outcome
    No significant changeSerious adverse events
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    with no increase in serious adverse events.
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of CagriSema, a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, compared with placebo, cagrilintide, or semaglutide monotherapy in overweight or obese individuals.
    Summary · context
    Seven randomized controlled trials (RCTs) (n = 8,069) were included.

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  12. 14HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In people with overweight or obesity, CagriSema was not linked to an increase in serious adverse events.

    In plain wordsIn people with overweight or obesity, the combination CagriSema was not linked to more serious side effects.

    Peptide
    Semaglutide
    Outcome
    No significant changeSerious adverse events
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    with no increase in serious adverse events.
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of CagriSema, a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, compared with placebo, cagrilintide, or semaglutide monotherapy in overweight or obese individuals.
    Summary · context
    Seven randomized controlled trials (RCTs) (n = 8,069) were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.